v3.26.1
Note 11 - Segments (Tables)
3 Months Ended
Mar. 31, 2026
Notes Tables  
Segment Reporting [Table Text Block]
   

Three Months Ended March 31,

 
   

2026

   

2025

 

Grant revenue

  $     $ 1,917,491  

Research and development expenses:

               

Dementia with Lewy bodies

    746,745       2,157,831  

Frontotemporal disorders (incl. nfvPPA)

    467,963       146,273  

Recovery after stroke

    308,951       252,542  

Other clinical* and nonclinical

    1,031,918       675,391  

Personnel costs, excluding stock-based compensation

    978,913       773,724  

Stock-based compensation

    126,710       123,702  

Other research and development expenses, including CMC**

    1,474,219       708,335  

Total research and development expenses

    5,135,419       4,837,798  

General and administrative expenses:

               

Personnel costs, excluding stock-based compensation

    1,316,430       1,111,094  

Stock-based compensation

    222,486       237,465  

Professional fees

    1,102,801       729,570  

Insurance, taxes and similar fees

    214,764       219,586  

Other general and administrative expenses, including IT, facilities, supplies and similar costs

    118,624       84,862  

Total general and administrative expenses

    2,975,105       2,382,577  

Other income

    146,366       408,850  

Net loss

  $ (7,964,158 )   $ (4,894,034 )